Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.

NCT00717236 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00717236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00717236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2008
Completion date
March 31, 2011
Enrollment
1,648 (actual)
Sites
181

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis